lobbying_activities: 2183998

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2183998	64fa9d70-bff8-4383-9a1c-f89e5b2e3c39	Q3	LUPIN PHARMACEUTICALS INC	401104766	LUPIN PHARMACEUTICALS INC	2018	third_quarter	PHA	CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.	HOUSE OF REPRESENTATIVES,SENATE		83325	0	0	2018-10-15T10:49:27.650000-04:00